CytoHub receives the Impact Award at The AI Summit @ Stanford
Contact us

Home / Cardia Therapeutics

Cardia Therapeutics · Crafting cells for cures

Rebuilding the failing heart with living muscle.

Mature, manufacturable human heart cells designed to replace the muscle a heart attack destroys.

Partner with CardiaHow HeartReady works

Developed and financed separately from the CytoHub data platform.

Illustration · heart adapted from Blausen Medical, CC BY 3.0

The unmet need

A heart attack leaves a permanent scar.

1Bheart muscle cells can die in a single heart attack
64Mpeople live with heart failure worldwide
~50%of heart-failure patients die within five years

No drug regrows heart muscle.

Only new cells can.

“My father survived the heart attack. The scar took him four years later.”

Rajib Biswas, PhD · CEO

Sources: Laflamme & Murry, Nat Biotechnol 2005 · GBD 2017, Lancet 2018 · JAHA 2023.

Independent evidence

Human heart cells have rebuilt the scar.

In primates, human stem-cell heart muscle cells engrafted into the scar and restored pumping function.

LVEF · pumping function after a heart attack

Pumping function rose from about 39 percent before treatment to about 50 percent at one month and about 62 percent at three months, while controls fell to about 40 percent. A normal heart is about 69 percent. Normal heart · ~69% ~39% ~50% ~62% Before cells 1 month 3 months
Treated Control · approximate, from reported baseline and changes; n = 2 treated, 1 control. Liu et al., Nat Biotechnol 2018. Not CytoHub data.
  1. 2014

    Stem-cell heart cells regenerate primate hearts

    Chong, Murry et al. · Nature

    Primate
  2. 2018

    10–12 point gain in pumping function at 12 weeks

    Liu et al. · Nature Biotechnology

    Primate
  3. 2024

    Heart-cell spheroids engraft durably

    Kobayashi, Tohyama et al. · Circulation

    Primate
  4. Now

    iPSC heart cells in a Phase 1/2 trial for heart failure

    Heartseed · LAPiS, NCT04945018

    Human

Known riskArrhythmias, linked to immature cells.

Our approachWe mature them first.

HeartReady™

Mature heart cells, off the shelf.

  1. 01In development

    Differentiate

    One stem-cell line, turned into heart muscle cells with a defined protocol.

  2. 02Safety unlock

    Mature

    Our enhanced maturation medium (EMM2/1) doubles a marker of adult heart rhythm, to lower arrhythmia risk.

    Volmert et al., Nat Commun 2023 · Aguirre Lab, MSU

  3. 03In development
    Bioreactor and the heart-cell aggregates it grows

    Manufacture

    Grown in 0.1–15 L bioreactors and frozen in vials, ready off the shelf.

  4. 04Planned

    Deliver

    Designed for minimally invasive, catheter-based injection into the damaged heart wall.

~31 daysfrom cell bank to frozen vial
  1. Day 0–15ExpandStem-cell seed train, 3 L bioreactor
  2. Day 15–30Differentiate & selectMesoderm → cardiac commitment → selection
  3. Day 31HarvestDissociate, wash, formulate
  4. Day 31Fill & freezeVial, controlled-rate freeze, liquid nitrogen

Tested at every stage: cell count, viability and flow cytometry. Release targets: ≥80% purity, ≥70% viability after thaw. Process in development; targets, not results.

Built on CytoHub data

The readouts that test drugs also test every lot.

The same imaging, electrophysiology and flow-cytometry readouts that power CardioVive are being built into HeartReady release testing: identity, purity and potency, lot after lot.

See the data wheel
  • Imagingidentity · structure
  • Electrophysiologymaturity · rhythm
  • Flow cytometrypurity per lot

Development path

Cells today. Tissue next. Organs in our lifetime.

Today · 2026–2031Under way

HeartReady

Live cells repair the scar.

Cell line, process development and CMC under way, then preclinical safety and first-in-human.

Tomorrow · 2032+Research

Tissue patches

Scale beyond single-cell repair.

Vascularized heart tissue for larger injuries.

Vision · 2040+Horizon

A full heart, on demand

No donor list. No rejection.

Bioprinted, transplantable organs.

Crafting cells for cures

Help us rebuild the failing heart.

Clinical, manufacturing and investment partnerships for HeartReady™.

Partner with CardiaInvestor enquiries